Oxford’s COVID-19 Vaccine Phase II ABSTRACT for-ChAdOx1 nCoV-19

I still think this is a very good Vaccine.  But will it be the BEST CANDIDATE for the World?  I sure don’t know, do you?

We show that a single dose of ChAdOx1 nCoV-19 elicits an increase in spike-specific antibodies by day 28 and neutralising antibody in all participants after a booster dose. High levels of neutralising antibody at baseline seen in a small number of participants probably indicates prior asymptomatic infection, as potential participants with recent COVID-19-like symptoms or with a history of positive PCR test for SARS-CoV-2 were excluded from the study. Individuals with high titres on the day of vaccination who received ChAdOx1 nCoV-19 were boosted by vaccination.